U.S. based pharmaceutical major Moderna has begun a multisite phase-3 clinical trial of the COVID-19 vaccine known as mRNA-1273.
The phase-3 clinical trial called the COVE (Coronavirus Efficacy) was meant to decide if the vaccine can prevent symptomatic COVID-19 in adults. The vaccine trial would hire 30,000 people at 89 sites across the country, with half the recipients receiving two shots of the vaccine 28 days apart and the other half receiving placebos.
The trial is designed to evaluate the safety of mRNA-1273 after two doses. The secondary goal aims to study whether the vaccine can prevent severe COVID-19 and seeks to answer if the vaccine can prevent death caused by COVID-19 and whether just one dose can prevent symptomatic COVID-19, among other objectives.